Diffuse Large B Cell Lymphoma Clinical Trials in Bethesda, Maryland

4 studies are recruiting for diffuse large b cell lymphoma in Bethesda, Maryland right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

   The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   American Oncology Partners, P.A. ( Site 0185), Bethesda, Maryland

   Locations

   275 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06717347 on ClinicalTrials.gov

2. Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

   Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and le…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03223610 on ClinicalTrials.gov

3. Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

   Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04002947 on ClinicalTrials.gov

4. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

   Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

   Stage

   Phase 1

   Ages

   18 and older

   Site

   American Oncology Partners of Maryland Pa, Bethesda, Maryland

   Locations

   115 in total

   Run by

   BeOne Medicines

   See if you can join NCT05006716 on ClinicalTrials.gov